{
    "clinical_study": {
        "@rank": "73960", 
        "arm_group": {
            "arm_group_label": "ACP-196", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk)\n      inhibitor, ACP-196, for the treatment of chronic lymphocytic leukemia (CLL)/small\n      lymphocytic lymphoma (SLL)"
        }, 
        "brief_title": "ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia", 
        "condition": [
            "Chronic Lymphocytic Leukemia", 
            "Small Lymphocytic Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women \u2265 18 years of age with a confirmed diagnosis of CLL/SLL, which has\n             relapsed after, or been refractory to, \u2265 2 previous treatments for CLL/SLL; however,\n             subjects with 17p deletion are eligible if they have relapsed after, or been\n             refractory to, 1 prior treatment for CLL/SLL.\n\n          -  Body weight \u2265 60 kg. (Note this inclusion requirement accounts for the fact that the\n             allometric scaling used to select the starting dose for this study is based on a\n             60-kg human)\n\n          -  ECOG performance status of \u2264 2.\n\n          -  Agreement to use contraception during the study and for 30 days after the last dose\n             of study drug if sexually active and able to bear children.\n\n          -  Willing and able to participate in all required evaluations and procedures in this\n             study protocol including swallowing capsules without difficulty.\n\n          -  Ability to understand the purpose and risks of the study and provide signed and dated\n             informed consent and authorization to use protected health information (in accordance\n             with national and local subject privacy regulations).\n\n        Exclusion Criteria:\n\n          -  Prior malignancy, except for adequately treated basal cell or squamous cell skin\n             cancer, in situ cervical cancer, or other cancer from which the subject has been\n             disease free for \u2265 2 years or which will not limit survival to < 2 years. Note: these\n             cases must be discussed with the Medical Monitor.\n\n          -  A life-threatening illness, medical condition or organ system dysfunction which, in\n             the investigator's opinion, could compromise the subject's safety, interfere with the\n             absorption or metabolism of ACP-196, or put the study outcomes at undue risk.\n\n          -  Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,\n             congestive heart failure, or myocardial infarction within 6 months of screening, or\n             any Class 3 or 4 cardiac disease as defined by the New York Heart Association\n             Functional Classification, or left ventricular ejection fraction (LVEF) \u2264 40%.\n\n          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or\n             resection of the stomach or small bowel or ulcerative colitis, symptomatic\n             inflammatory bowel disease, or partial or complete bowel obstruction.\n\n          -  Any immunotherapy within 4 weeks of first dose of study drug.\n\n          -  For subjects with recent chemotherapy or experimental therapy the first dose of study\n             drug must occur after 5 times the half-life of the agent(s).\n\n          -  Relapsed after, or refractory to, prior BTK inhibitor therapy.\n\n          -  Concomitant use of medicines known to cause QT prolongation or Torsades de pointes\n             (see Appendix 1).\n\n          -  Central nervous system (CNS) involvement by lymphoma\n\n          -  Grade \u2265 2 toxicity (other than alopecia) continuing from prior anticancer therapy\n             including radiation.\n\n          -  Known history of human immunodeficiency virus (HIV) or active infection with\n             hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active\n             systemic infection.\n\n          -  Major surgery within 4 weeks before first dose of study drug.\n\n          -  ANC < 0.75 x 109/L or platelet count < 50 x 109/L unless there is bone marrow\n             involvement.\n\n          -  Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x\n             ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or\n             alanine aminotransferase (ALT) > 2.5 x ULN unless disease related.\n\n          -  Serum amylase > 1.5 x ULN or serum lipase > 1.5 x ULN.\n\n          -  Significant screening ECG abnormalities including left bundle branch block, 2nd\n             degree AV block type II, 3rd degree block, Grade 2 or higher bradycardia, and QTc \u2265\n             480 ms.\n\n          -  Cardiac troponin I or cardiac troponin T levels above the limit of normal as\n             specified by the manufacturer.\n\n          -  Lactating or pregnant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029443", 
            "org_study_id": "ACE-CL-001"
        }, 
        "intervention": {
            "arm_group_label": "ACP-196", 
            "intervention_name": "ACP-196", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Bruton's tyrosine kinase inhibitor", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia", 
        "overall_contact": {
            "email": "e.robbie@acerta-pharma.com", 
            "last_name": "Edward P Robbie, MPH", 
            "phone": "+1 650 591 4026"
        }, 
        "overall_contact_backup": {
            "email": "t.navarro@acerta-pharma.com", 
            "last_name": "Tasheda Navarro, BS", 
            "phone": "+1 650 670 5439"
        }, 
        "overall_official": {
            "affiliation": "Acerta Pharma", 
            "last_name": "Ahmed Hamdy, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determine the Maximum Tolerated Dose", 
            "safety_issue": "Yes", 
            "time_frame": "Cycle 1 (28 Days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029443"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Acerta Pharma BV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acerta Pharma BV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}